Pemetrexed (Alimta)

DRUG11 trials

Conditions

Advanced Non Small Cell Lung CancerCTLA4Intrathecal Drug DeliveryLeptomeningeal MetastasisMET Exon 14 MutationMelanomaNSCLCNSCLC (Advanced Non-small Cell Lung Cancer)

Phase 1

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Active, not recruitingNCT05180799

BioAtla, Inc.Melanoma, NSCLC

Start: 2022-08-03End: 2026-06-30Target: 320Updated: 2025-06-15

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

RecruitingNCT06762080

Guangzhou Medical UniversityLeptomeningeal Metastasis

Start: 2025-03-07End: 2026-06-01Target: 36Updated: 2025-05-20

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

RecruitingNCT06809530

Guangzhou Medical UniversityCTLA4, Leptomeningeal Metastasis, PD-1 Inhibitor +2

Start: 2025-03-17End: 2026-07-01Target: 34Updated: 2025-05-18

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

RecruitingNCT06809517

Guangzhou Medical UniversityIntrathecal Drug Delivery, Leptomeningeal Metastasis

Start: 2025-03-18End: 2026-05-01Target: 34Updated: 2025-05-20

Phase 2

Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy

CompletedNCT00630149

Sun Yat-sen UniversityNasopharyngeal Neoplasms

Start: 2007-11-30End: 2012-01-31Updated: 2012-02-16

Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations

CompletedNCT00891579

Chinese Society of Lung CancerNon Small Cell Lung Cancer

Start: 2009-02-28End: 2012-11-30Updated: 2012-12-10

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

RecruitingNCT07001618

Gustave Roussy, Cancer Campus, Grand ParisNSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2025-11-17End: 2032-09-01Target: 162Updated: 2026-04-03

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

Not yet recruitingNCT07234058

Intergroupe Francophone de Cancerologie ThoraciquePleural Mesotheliomas

Start: 2026-02-01End: 2029-09-01Target: 126Updated: 2026-02-11

Phase 3

Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)

CompletedNCT00440414

Hellenic Oncology Research GroupNon Small Cell Lung Cancer

Start: 2006-04-30End: 2010-04-30Target: 320Updated: 2010-08-19

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

RecruitingNCT06908993

Intergroupe Francophone de Cancerologie ThoraciqueAdvanced Non Small Cell Lung Cancer, MET Exon 14 Mutation

Start: 2025-12-09End: 2028-07-15Target: 133Updated: 2025-12-17

Unknown Phase

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

NCT00903292

National Cheng-Kung University HospitalNon-Small Cell Lung Cancer

Start: 2009-03-31End: 2010-12-31Target: 52Updated: 2009-05-18

Related Papers

Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.

Journal of Clinical Oncology2024-06-012 citations

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.

2014-10-0350 citations